Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)

Rekrutierend

NCT-Nummer:
NCT05568225

Studienbeginn:
November 2022

Letztes Update:
10.04.2024

Wirkstoff:
Etavopivat

Indikation (Clinical Trials):
Preleukemia, Anemia, Myelodysplastic Syndromes

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Forma Therapeutics, Inc.

Collaborator:
-

Studienleiter

Clinical Transparency (dept. 2834), MD
Study Director
Novo Nordisk A/S

Kontakt

Studienlocations
(3 von 15)

Universitoetsklinikum Heidelberg
Heidelberg
(Baden-Württemberg)
GermanyRekrutierend» Google-Maps
Universitaetsklinikum Muenster
Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
Universitoetsklinikum Halle (Saale)
Münster
(Nordrhein-Westfalen)
GermanyRekrutierend» Google-Maps
University of Miami Hospital and Clinics
33136 Miami
United StatesRekrutierend» Google-Maps
University of Maryland Greenebaum Comprehensive Cancer Center
21201 Baltimore
United StatesRekrutierend» Google-Maps
Maimonides Medical Center
11219 Brooklyn
United StatesRekrutierend» Google-Maps
Columbia University Irving Medical Center
10032 New York
United StatesRekrutierend» Google-Maps
Baptist Clinical Research Institute
38120 Memphis
United StatesRekrutierend» Google-Maps
University of British Columbia - St. Paul's Hospital
V6Z 2K5 Vancouver
CanadaRekrutierend» Google-Maps
Nice University Hospital - Hôpital de l'Archet
06200 Route De Saint-Antoine
FranceRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Brief Summary:

The purpose of this study is to evaluate the safety and efficacy of etavopivat (FT-4202) for

the treatment of anemia in adult patients with very low risk, low risk, or intermediate risk

MDS.

Ein-/Ausschlusskriterien

INCLUSION CRITERIA:

1. Patient has provided documented informed consent; the informed consent form (ICF) must

be reviewed and signed by each patient prior to any study-related

assessments/procedures being conducted.

2. Age ≥ 18 years at time of first dose.

3. Patients, if female and of childbearing potential, must agree to use acceptable

methods of contraception and agree not to donate ova from study start to 90 days after

the last dose of study drug, and who if male are willing to use acceptable methods of

contraception and agree not to donate sperm, from study start to 90 days after the

last dose of study drug.

4. Documented diagnosis of idiopathic/de novo MDS according to World Health Organization

(WHO) classification that meets the IPSS-R classification of very low, low, or

intermediate risk disease, and:

- < 5% blasts in bone marrow based on local pathology review

- < Intermediate risk cytogenetic abnormalities per IPSS-R

5. Anemia defined as:

- Non-transfusion dependent (NTD): Subjects with mean Hb concentration < 10.0 g/dL

of 2 measurements (1 performed within 3 days prior to Day 1 and the other

performed 7 to 28 days prior to Day 1, not influenced by RBC transfusion within 7

days of measurement) and < 3 RBC transfusions for anemia in the prior 16 weeks

before Day 1 of etavopivat dosing

OR

- Transfusion dependent (TD): Subjects having received ≥ 3 units of RBCs for the

treatment of anemia within 16 weeks prior to Day 1

6. Serum erythropoietin level > 200 U/L, OR, if ≤ 200 U/L, subject is non-responsive,

refractory, or intolerant to erythropoiesis-stimulating agents, or

erythropoiesis-stimulating agents are contraindicated or unavailable.

7. ECOG performance status of ≤ 2

8. Subject is non-responsive, refractory, or intolerant to luspatercept, or luspatercept

is contraindicated or not indicated.

9. No alternative treatment options are available and/or appropriate for the subject, at

the discretion of the investigator.

10. Patient is willing and able to adhere to the study visit schedule and other protocol

requirements

EXCLUSION CRITERIA:

[MDS History]

1. MDS associated with del 5q cytogenetic abnormality and known TP53 abnormality

2. Therapy-associated MDS (eg. t-MDS) that is known to have arisen as the result of

chemical injury or treatment with chemotherapy and/or radiation for other diseases

3. Known history of acute myeloid leukemia (AML)

[Medical Conditions]

4. Female who is breast feeding or pregnant

5. Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies,

or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding

6. Absolute neutrophil count < 500/µL (0.5 x 10^9/L)

7. Platelet count < 50,000/µL (50 x 10^9/L) without transfusion support within 2 weeks

8. Hepatic dysfunction characterized by:

- Alanine aminotransferase (ALT) > 5.0 × upper limit of normal (ULN)

- Total bilirubin > 3.0 × ULN

- History of cirrhosis

9. Severe renal dysfunction (estimated glomerular filtration rate at the Screening visit;

calculated by the local laboratory < 30 mL/min/1.73 m^2 ) or on chronic dialysis.

10. Patients with clinically significant and active bacterial, fungal, parasitic, or viral

infection.

- Patients with acute bacterial, fungal, parasitic, or viral infection requiring

systemic therapy should delay Screening/ enrollment until active therapy has been

completed.

- Patients with acute viral infections without available therapies (eg, coronavirus

disease 2019 [COVID-19]) should delay Screening/ enrollment until the acute

infection has resolved.

Note: Infection prophylaxis is allowed.

11. Known human immunodeficiency virus (HIV) positivity

12. Active infection with hepatitis B virus (hepatitis B surface antigen [HepBsAg] and

hepatitis B core antibody [HepBcAb] positive)

13. Active hepatitis C infection

14. History of malignancy, other than MDS, within the past 2 years prior to treatment Day

1 requiring systemic chemotherapy and/or radiation.

- Patients with malignancy considered surgically cured are eligible (eg,

non-melanoma skin cancer, carcinoma in situ of the cervix, or carcinoma in situ

of the breast)

- Patients with incidental histologic findings of prostate cancer (T1a or T1b) are

eligible

15. History of unstable or deteriorating cardiac or pulmonary disease within 6 months

prior to consent including but not limited to the following:

- Unstable angina pectoris or myocardial infarction or elective coronary

intervention

- Heart disease, heart failure as classified by the New York Heart Association

classification 3 or higher, or significant arrhythmia requiring treatment,

- Pulmonary fibrosis or pulmonary hypertension which are clinically significant ie,

≥ Grade 3 National Cancer Institute (NCI) Common Terminology Criteria for Adverse

Events (CTCAE) version 4.0 (or higher)

16. Uncontrolled hypertension, defined as repeated elevation of diastolic blood pressure ≥

100 mmHg despite adequate treatment

17. Any condition affecting drug absorption, such as major surgery involving the stomach

or small intestine (prior cholecystectomy is acceptable).

[Prior/Concomitant Therapy]

18. Prior treatment with azacitidine (injectable or oral) or decitabine

19. Use of erythropoietin, other hematopoietic growth factor treatment or lenalidomide

within 30 days of starting study treatment or anticipated need for such agents during

the study.

20. Prior use of luspatercept:

- NTD patients must not have received luspatercept within 30 days prior to Day 1

treatment

- TD patients must not have received luspatercept within 16 weeks prior to Day 1

treatment

21. Receiving or use of concomitant medications that are strong inducers of cytochrome

P450 (CYP)3A4/5 (see Appendix F) within 2 weeks of starting study treatment or

anticipated need for such agents during the study.

22. Prior allogeneic or autologous stem cell transplant

23. Initiation of a new chelation therapy within 3 months before the first dose of study

treatment.

[Prior/Concurrent Clinical Study Experience]

24. Participated in another clinical trial of an investigational agent (or medical device)

within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is

currently participating in another trial of an investigational agent (or medical

device).

[Other Exclusions]

25. Medical, psychological, or behavioral conditions, which, in the opinion of the

Investigator, may preclude safe participation, confound study interpretation,

interfere with compliance, or preclude informed consent.

Studien-Rationale

Primary outcome:

1. The hematologic improvement based on an erythroid response (HI -E) ≥ 8 weeks duration in patients with MDS after 16 weeks of etavopivat treatment (Time Frame - 16 weeks):
Measure in number of patient incidence This endpoint will be based on the combined incidence of: Non-transfusion dependent (NTD) patients: ≥ 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained ≥ 8 consecutive weeks Low transfusion burden (LTB) patients: absence of any transfusion for ≥ 8 consecutive weeks High transfusion burden (HTB) patients: reduction by ≥ 50% of red blood cell (RBC) units for ≥ 8 consecutive weeks



Secondary outcome:

1. The HI-E ≥ 8 weeks duration in this population of patients after 24 and 48 weeks of etavopivat treatment (Time Frame - 24 and 48 weeks):
Measure in number of patient incidence This endpoint will be based on the combined incidence of: Non-transfusion dependent (NTD) patients: ≥ 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained ≥ 8 consecutive weeks Low transfusion burden (LTB) patients: absence of any transfusion for ≥ 8 consecutive weeks High transfusion burden (HTB) patients: reduction by ≥ 50% of red blood cell (RBC) units for ≥ 8 consecutive weeks

2. The HI-E ≥ 16 weeks duration in this population of patients after 24 and 48 weeks of etavopivat treatment (Time Frame - 24 and 48 weeks):
Measure in number of patient incidence This endpoint will be based on the combined incidence of: Non-transfusion dependent (NTD) patients: ≥ 1.5 g/dL increase in hemoglobin (Hb) from baseline maintained ≥ 16 consecutive weeks Low transfusion burden (LTB) patients: absence of any transfusion for ≥ 16 consecutive weeks High transfusion burden (HTB) patients: reduction by ≥ 50% of red blood cell (RBC) units for ≥ 16 consecutive weeks

3. Incidence of AEs, serious adverse events (SAEs), and AEs related to etavopivat (Time Frame - 4(first 6 participants), 16, 24, and 48 weeks):
Measure in number of patient incidences

4. Number of premature discontinuations, dose interruptions, and dose reductions (Time Frame - 4(first 6 participants), 16, 24, and 48 weeks):
Measure in number of patient incidences

5. Overall response rate for MDS (Time Frame - 16, 24, and 48 weeks.):
Measure in number of patient incidence, per Chelson, 2006 International Working Group [IWG] Criteria

6. Duration of response (Time Frame - 16, 24, and 48 weeks.):
Measure in number of days, per 2006 IWG Criteria

7. Percentage of participants who achieved RBC transfusion independence in participants with LTB or HTB at study entry (Time Frame - 16, 24, and 48 weeks.):
Measure in percentage

8. Change from baseline in RBC units transfused in patients with NTD, LTB or HTB at study entry (Time Frame - 16, 24, and 48 weeks.):
Measure in RBC units

9. Participants who achieved a hematologic improvement in neutrophil (Time Frame - 16, 24, and 48 weeks.):
Measure in number of patient incidence

10. Participants who achieved a hematologic improvement in platelet response (Time Frame - 16, 24, and 48 weeks.):
Measure in number of patient incidence

11. Change from baseline in mean serum ferritin (Time Frame - 16, 24, and 48 weeks.):
Measure in ng/mL

12. Change from baseline in mean daily dose of iron chelation therapy (Time Frame - 16, 24, and 48 weeks.):
Measure in dose unit

13. Overall survival (Time Frame - 16, 24, and 48 weeks.):
Measure in number of patient incidence

Geprüfte Regime

  • Etavopivat (FT-4202):
    400 mg once daily

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"A Study of Etavopivat for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.